Glucose-responsive oral insulin delivery platform for one treatment a day in diabetes
Glucose-responsive oral insulin delivery platform for one treatment a day in diabetes
复制标题
DOI：
10.1016/j.matt.2021.08.011
复制
发表时间：
2021-10
期刊：
影响因子：
18.9
通讯作者：
Yufen Xiao;Zhongmin Tang;Xiangang Huang;John Joseph;Wei Chen;Chuang Liu;Jun Zhou;Na Kong;N. Joshi;Jianzhong Du;Wei Tao
中科院分区：
文献类型：
--
作者：
Yufen Xiao;Zhongmin Tang;Xiangang Huang;John Joseph;Wei Chen;Chuang Liu;Jun Zhou;Na Kong;N. Joshi;Jianzhong Du;Wei Tao
口服胰岛素在治疗糖尿病方面非常方便，但仍会受到胃肠道的恶劣影响。在此，我们开发了一种基于葡萄糖响应性聚合物纳米颗粒（NPs）的智能口服胰岛素平台，该平台具有以下优点：（1）保护装载胰岛素对胃肠道的完整性和生物利用度，（2）通过新生儿Fc受体介导的运输克服肠上皮屏障，以及（3）仅依赖于血糖水平按需释放胰岛素，以避免由不安全剂量的胰岛素引起的高血糖和低血糖。值得注意的是，我们的口服 NP 对 1 型糖尿病小鼠的治疗效果延长至长达 16 小时。据我们所知，这是迄今为止报道的此类口服胰岛素平台中有效时间最长的，并且可以将胰岛素给药频率减少到每天一次。该平台可能有助于口服生物制剂治疗糖尿病和相关并发症。
Oral delivery of insulin is of great convenience in treating diabetes but is still subject to the harsh gastrointestinal tract. Herein, we developed an intelligent oral insulin platform based on glucose-responsive polymeric nanoparticles (NPs), which possess the following advantages: (1) protect the integrity and bioavailability of loaded insulin against gastrointestinal tract, (2) overcome the intestinal epithelial barriers via neonatal Fc receptor-mediated transport, and (3) on-demand release of insulin dependent solely on blood glucose levels to avoid hyperglycemia and hypoglycemia caused by unsafe doses of insulin. Notably, our oral NPs extended the therapeutic effect to up to 16 h in type 1 diabetic mice. To our knowledge, this is the longest effective time among such types of oral insulin platforms reported to date and may reduce the frequency of insulin administration to once daily. This platform might be useful for the oral delivery of biologics in treating diabetes and related complications.